CN101657445B - 治疗青光眼或眼内压升高的γ内酰胺 - Google Patents

治疗青光眼或眼内压升高的γ内酰胺 Download PDF

Info

Publication number
CN101657445B
CN101657445B CN2008800120472A CN200880012047A CN101657445B CN 101657445 B CN101657445 B CN 101657445B CN 2008800120472 A CN2008800120472 A CN 2008800120472A CN 200880012047 A CN200880012047 A CN 200880012047A CN 101657445 B CN101657445 B CN 101657445B
Authority
CN
China
Prior art keywords
another embodiment
group
compound
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800120472A
Other languages
English (en)
Chinese (zh)
Other versions
CN101657445A (zh
Inventor
D·W·奥尔德
W·B·艾姆
V·X·恩戈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN101657445A publication Critical patent/CN101657445A/zh
Application granted granted Critical
Publication of CN101657445B publication Critical patent/CN101657445B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2008800120472A 2007-02-15 2008-02-08 治疗青光眼或眼内压升高的γ内酰胺 Expired - Fee Related CN101657445B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89018107P 2007-02-15 2007-02-15
US60/890,181 2007-02-15
PCT/US2008/053386 WO2008100809A1 (en) 2007-02-15 2008-02-08 Gamma-lactams for the treatment of glaucoma or elevated intraocular pressure

Publications (2)

Publication Number Publication Date
CN101657445A CN101657445A (zh) 2010-02-24
CN101657445B true CN101657445B (zh) 2013-06-05

Family

ID=39511007

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800120472A Expired - Fee Related CN101657445B (zh) 2007-02-15 2008-02-08 治疗青光眼或眼内压升高的γ内酰胺

Country Status (12)

Country Link
US (1) US8362054B2 (https=)
EP (1) EP2118094B1 (https=)
JP (1) JP5566696B2 (https=)
KR (1) KR20090109587A (https=)
CN (1) CN101657445B (https=)
AU (1) AU2008216499B2 (https=)
BR (1) BRPI0807600A2 (https=)
CA (1) CA2678191A1 (https=)
ES (1) ES2404169T3 (https=)
MX (1) MX2009008734A (https=)
NZ (1) NZ598945A (https=)
WO (1) WO2008100809A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009055289A2 (en) * 2007-10-23 2009-04-30 Allergan, Inc. Therapeutic substituted lactams
CN117500791A (zh) * 2021-03-08 2024-02-02 阿比奥尼克斯制药公司 可用于治疗肝脏疾病的化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2451392A1 (en) * 2001-07-16 2003-01-30 F. Hoffmann-La Roche Ag Prostaglandin analogues as ep4 receptor agonists
KR100437972B1 (ko) * 2001-10-27 2004-07-02 한국과학기술연구원 피롤리디논 유도체, 이의 제조 방법 및 이를 포함하는제약 조성물
AU2003211574A1 (en) * 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
JP4754820B2 (ja) * 2002-06-10 2011-08-24 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγラクタムおよびその使用
WO2004037813A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7091231B2 (en) 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
JP2008538547A (ja) 2005-03-09 2008-10-30 ロジャー・ウィリアムズ・ホスピタル 甲状腺刺激ホルモン放出ホルモン類縁体及び使用方法
CA2599425C (en) * 2005-03-10 2013-04-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2007109578A2 (en) * 2006-03-20 2007-09-27 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists

Also Published As

Publication number Publication date
JP5566696B2 (ja) 2014-08-06
MX2009008734A (es) 2009-08-25
EP2118094A1 (en) 2009-11-18
AU2008216499B2 (en) 2014-04-17
AU2008216499A1 (en) 2008-08-21
ES2404169T3 (es) 2013-05-24
WO2008100809A1 (en) 2008-08-21
KR20090109587A (ko) 2009-10-20
NZ598945A (en) 2013-08-30
CN101657445A (zh) 2010-02-24
CA2678191A1 (en) 2008-08-21
US8362054B2 (en) 2013-01-29
JP2010519208A (ja) 2010-06-03
BRPI0807600A2 (pt) 2014-07-22
US20100168189A1 (en) 2010-07-01
EP2118094B1 (en) 2013-04-17

Similar Documents

Publication Publication Date Title
JP5247680B2 (ja) １２−アリールまたはヘテロアリールプロスタグランジンアナログ
JP5410438B2 (ja) 治療用置換ラクタム類
US20080015219A1 (en) Therapeutic compounds
AU2007272683A1 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2008091818A1 (en) Substituted arylcyclopentenes as therapeutic agents
AU2007249443B2 (en) Isothiazolidines useful in the treatment of ocular hypertensive conditions
CN101657445B (zh) 治疗青光眼或眼内压升高的γ内酰胺
JP5570211B2 (ja) 治療化合物
JP2010516817A (ja) 治療薬としての置換ガンマラクタム類
JP5269772B2 (ja) 治療用シクロペンタン誘導体
BRPI0709720A2 (pt) compostos terapÊuticos
JP2009535421A (ja) 治療用シクロペンタン誘導体
AU2008208032B2 (en) Substituted arylcylopentenes as therapeutic agents
BRPI0712500A2 (pt) compostos terapêuticos de pirrolidina
US20090016981A1 (en) Therapeutic compounds
US20080033023A1 (en) Therapeutic compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130605

Termination date: 20150208

EXPY Termination of patent right or utility model